Related Experiment Videos
New agents for Type 2 diabetes
1Diabetes Resource Centre, Selly Oak Hospital, Birmingham, UK.
Abstract:
Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality. They also reduce chronic diabetic complications, but they do not eliminate them. Thus, new agents with novel actions are required to complement and extend the capabilities of existing treatments. Insulin resistance and beta-cell failure, which are crucial components in the pathogenesis of Type 2 diabetes, remain the underlying targets for new drugs. Recently introduced agents include a short-acting non-sulphonylurea insulin-releaser, repaglinide, which synchronizes insulin secretion with meal digestion in order to reduce post-prandial hyperglycaemia. The thiazolidinedione drugs, troglitazone, rosiglitazone and pioglitazone represent a new class of agonists for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARgamma). PPARgamma increases the transcription of certain insulin-sensitive genes, thereby improving insulin sensitivity. The intestinal lipase inhibitor orlistat and the satiety-inducer sibutramine are new weight-reducing agents that may benefit glycaemic control in obese Type 2 diabetes patients. Several further new insulin-releasing agents, and agents to retard carbohydrate digestion and modify lipid metabolism stand poised to enter the market. The extent to which they will benefit glycaemic control remains to be seen. However, the prospect of permanently arresting or reversing the progressive deterioration of Type 2 diabetes continues to evade therapeutic capture.
Insights
New treatments for Type 2 diabetes mellitus aim to improve metabolic profiles and reduce complications. Novel agents targeting insulin resistance and beta-cell function are being developed to complement existing therapies.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Current Type 2 diabetes mellitus treatments offer partial metabolic improvement and complication reduction.
- Novel therapeutic strategies are needed to address the underlying pathogenesis of insulin resistance and beta-cell failure.
Purpose of the Study:
- To review emerging therapeutic agents for Type 2 diabetes mellitus.
- To discuss novel mechanisms of action targeting key diabetes pathologies.
Main Methods:
- Review of recently introduced and pipeline pharmacologic agents for Type 2 diabetes.
- Analysis of drug classes including insulin secretagogues, insulin sensitizers, lipase inhibitors, and satiety inducers.
Main Results:
- Repaglinide synchronizes insulin secretion to reduce post-prandial hyperglycemia.
- Thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) activate PPARgamma, enhancing insulin sensitivity.
- Orlistat and sibutramine offer potential benefits for glycemic control in obese patients through weight reduction.
Conclusions:
- Emerging agents offer novel approaches to managing Type 2 diabetes.
- While promising, the long-term impact of these new agents on halting or reversing disease progression requires further investigation.